Semaglutide
Semaglutide is a breakthrough, long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist that revolutionized modern obesity and metabolic management. FDA-approved under the brand names Wegovy and Ozempic, it combats profound metabolic resistance by correcting broken satiety signaling and restoring pancreatic efficiency. Clinically, it has established the gold standard for non-surgical weight loss, demonstrating a highly consistent 15% reduction in baseline body weight while simultaneously offering robust cardiovascular risk reduction and neuroprotective benefits in phase three trials.
Quick Stats
Scientific Data
Mechanism of Action
Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist with 94% homology to native human GLP-1. It mimics the incretin hormone GLP-1, which is naturally released after eating. Its mechanism involves multiple pathways: (1) stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner, (2) suppressing glucagon release from alpha cells, (3) slowing gastric emptying to increase satiety, and (4) acting on hypothalamic appetite centers to reduce food intake.
Semaglutide has a 7-day half-life due to albumin binding and DPP-4 enzyme resistance, allowing once-weekly dosing. It is FDA-approved as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus in oral formulation. Clinical trials (STEP program) demonstrated 15-17% body weight reduction at the 2.4 mg dose.
Source: FDA Label (Wegovy), PMID: 33567185 (STEP 1)
Background & History
Semaglutide was developed by Novo Nordisk through systematic modification of native GLP-1 to resist DPP-4 degradation. Its C18 fatty acid chain enables albumin binding, extending half-life to 7 days. FDA-approved as Ozempic in 2017 for type 2 diabetes and as Wegovy in 2021 for chronic weight management — the first weight loss drug approved for obesity as a chronic disease. The STEP trial program (2021) demonstrated 15–17% body weight reduction, redefining obesity pharmacotherapy.
Key Clinical Metrics
Peak Weight Loss
Achieved at target maintenance dose (2.4mg) over 68 weeks.
Receptor Targets
94% human homology, single-receptor agonist.
Half-Life
Long duration of action strongly supports once-weekly administration.
Published Trial Data
Semaglutide 2.4 mg for Chronic Weight Management
Shown an average of 14.9% body weight reduction in adults with obesity over 68 weeks.
Semaglutide 2.4 mg in Type 2 Diabetes
Demonstrated 9.6% body weight reduction in adults with both obesity and type 2 diabetes.
Two-Year Effects of Semaglutide 2.4 mg
Confirmed sustained weight loss maintenance of 15.2% over 104 weeks without significant plateauing decay.
Cardiovascular Outcomes Trial
Reduced risk of major adverse cardiovascular events by 20% in adults with overweight/obesity and established CVD without diabetes.
Research Use Cases
- ✓Type 2 diabetes: glycemic control with cardiorenal protection
- ✓Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
- ✓Cardiovascular risk reduction in T2D (SELECT trial: 20% CV event reduction)
- ✓Non-alcoholic steatohepatitis (NASH) — Phase III trials ongoing
- ✓Compounded research: body recomposition protocols
Dosing Protocol
| Typical Dose | 0.25-2.4 mg/week |
| Frequency | 1× weekly |
| Half-Life | ~168 hours (7 days) |
| Common Vial Sizes | 3 mg, 5 mg |
Dosing Protocols
Initiation (Weeks 1-4)
Escalation (Weeks 5-8)
Escalation (Weeks 9-12)
Maintenance (Wegovy max)
Administration
Expected Timeline
Who Is It For?
Obesity / Chronic Weight Management
HighFDA-approved (Wegovy). Clinical STEP trials showed 15-17% average total body weight reduction.
Type 2 Diabetes
HighFDA-approved (Ozempic). Strong HbA1c reduction with secondary cardiovascular benefits (SUSTAIN-6, SELECT).
Reconstitution Example
Safety & Considerations
Semaglutide is FDA-approved for type 2 diabetes and weight management. Common side effects include nausea, vomiting, diarrhea (usually transient during dose escalation). Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Not recommended during pregnancy.
Regulatory & Legal Status
FDA-approved as Ozempic® (T2D) and Wegovy® (obesity)
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Prescription Drug
US Compounding: Available via licensed pharmacy Rx
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Contraindicated: personal/family history of medullary thyroid carcinoma or MEN2. Do not combine with other GLP-1 agonists or DPP-4 inhibitors (additive effects without clear benefit). May require insulin dose adjustment in T2D patients. Slowed gastric emptying affects absorption of oral medications — separate timing by 1 hour.
Synergies & Common Stacks
NOT a synergy — combining two GLP-1 agonists is contraindicated due to additive GI side effects and risk of hypoglycemia without additional benefit.
BPC-157's GI protective effects may help manage GLP-1-induced nausea and gastric slowing during dose escalation, supporting tolerability.
Semaglutide vs. Tirzepatide
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | GIP + GLP-1 dual receptor agonist |
| Peak Weight Loss | 14.9–17% body weight (STEP trials) | 22.5% body weight (SURMOUNT-1) |
| FDA Approval | Ozempic® (T2D) / Wegovy® (obesity) | Mounjaro® (T2D) / Zepbound® (obesity) |
| Half-Life | ~7 days (once weekly) | ~5 days (once weekly) |
| GI Side Effects | Moderate — nausea most common | Similar profile; slightly more at peak dose |
| Starting Dose | 0.25 mg/week (escalated over 20 wks) | 2.5 mg/week (escalated over 20 wks) |
| Cost (branded) | ~$900–1,100/mo list price | ~$1,000–1,200/mo list price |
Verdict: Tirzepatide delivers greater weight loss due to its dual receptor mechanism; semaglutide has a longer clinical track record and broader global availability. For maximum weight loss, tirzepatide is the better choice; for established safety data, semaglutide leads.
Semaglutide vs. Liraglutide
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 agonist (same class) |
| Peak Weight Loss | 14.9–17% | ~8% (SCALE trial) |
| Dosing Schedule | Once weekly injection | Daily injection |
| FDA Approval | Ozempic® / Wegovy® | Victoza® (T2D) / Saxenda® (obesity) |
| Cardiovascular | Proven CV risk reduction (SUSTAIN-6) | Proven CV risk reduction (LEADER) |
| Convenience | High — once weekly dosing | Low — daily injection required |
Verdict: Semaglutide is the clear successor to liraglutide: superior weight loss, once-weekly dosing convenience, and comparable safety profile. Liraglutide is primarily used today where semaglutide is unavailable or not covered.
Dosing Quick Reference
Frequently Asked Questions
What is the standard semaglutide dose escalation?▼
How do I calculate semaglutide syringe units?▼
Can I take semaglutide with other peptides?▼
What is the difference between Ozempic and Wegovy?▼
References
- Wilding et al. “"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)".” New England Journal of Medicine (2021). PMID: 33567185
- Lincoff et al. “"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)".” New England Journal of Medicine (2023). PMID: 37952131
📚 Related Articles
Get Semaglutide from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review